JP2024544625A5 - - Google Patents

Info

Publication number
JP2024544625A5
JP2024544625A5 JP2024532155A JP2024532155A JP2024544625A5 JP 2024544625 A5 JP2024544625 A5 JP 2024544625A5 JP 2024532155 A JP2024532155 A JP 2024532155A JP 2024532155 A JP2024532155 A JP 2024532155A JP 2024544625 A5 JP2024544625 A5 JP 2024544625A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
composition according
alkyl
bid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532155A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544625A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/061652 external-priority patent/WO2023100134A1/en
Publication of JP2024544625A publication Critical patent/JP2024544625A/ja
Publication of JP2024544625A5 publication Critical patent/JP2024544625A5/ja
Pending legal-status Critical Current

Links

JP2024532155A 2021-12-02 2022-12-01 がんを処置するためのcdk2阻害剤およびcdk4阻害剤を含む方法および投薬レジメン Pending JP2024544625A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163285457P 2021-12-02 2021-12-02
US63/285,457 2021-12-02
PCT/IB2022/061652 WO2023100134A1 (en) 2021-12-02 2022-12-01 Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer

Publications (2)

Publication Number Publication Date
JP2024544625A JP2024544625A (ja) 2024-12-03
JP2024544625A5 true JP2024544625A5 (cg-RX-API-DMAC10.html) 2025-11-21

Family

ID=84462534

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532155A Pending JP2024544625A (ja) 2021-12-02 2022-12-01 がんを処置するためのcdk2阻害剤およびcdk4阻害剤を含む方法および投薬レジメン

Country Status (12)

Country Link
US (1) US20250041277A1 (cg-RX-API-DMAC10.html)
EP (1) EP4440575A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024544625A (cg-RX-API-DMAC10.html)
KR (1) KR20240112932A (cg-RX-API-DMAC10.html)
CN (1) CN118647379A (cg-RX-API-DMAC10.html)
AU (2) AU2022402512A1 (cg-RX-API-DMAC10.html)
CA (1) CA3241001A1 (cg-RX-API-DMAC10.html)
IL (1) IL312980A (cg-RX-API-DMAC10.html)
MX (1) MX2024006747A (cg-RX-API-DMAC10.html)
TW (1) TWI873485B (cg-RX-API-DMAC10.html)
WO (1) WO2023100134A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202404615B (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
EP4604961A1 (en) * 2022-10-18 2025-08-27 Pfizer Inc. Compounds for the treatment of cancer
EP4719405A1 (en) * 2023-06-02 2026-04-08 Pfizer Inc. Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
WO2025202871A1 (en) * 2024-03-27 2025-10-02 Pfizer Inc. Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor
WO2025202854A1 (en) * 2024-03-27 2025-10-02 Pfizer Inc. Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers
WO2026133192A1 (en) * 2024-12-20 2026-06-25 Pfizer Inc. Combination therapies using cdk4 inhibitors with pd-1 axis binding antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
CN118286225A (zh) 2018-04-26 2024-07-05 辉瑞公司 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物
CA3128155C (en) 2019-01-31 2023-09-19 Pfizer Inc. 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2

Similar Documents

Publication Publication Date Title
JP2021522275A5 (cg-RX-API-DMAC10.html)
CN1332974C (zh) 抗雌激素甾族化合物、有关的药学组合物和使用方法
JP2023541522A5 (cg-RX-API-DMAC10.html)
JP7595413B2 (ja) 15-pgdh阻害剤とコルチコステロイドおよび/またはtnf阻害剤との組み合わせならびにその使用
US8143410B2 (en) Kinase inhibitors
US9708311B2 (en) Benzimidazole derivatives as EP4 antagonists
US8455656B2 (en) Kinase inhibitors
JP2008500988A5 (cg-RX-API-DMAC10.html)
JP2021501754A5 (cg-RX-API-DMAC10.html)
JP2008500990A5 (cg-RX-API-DMAC10.html)
JP2014528464A5 (cg-RX-API-DMAC10.html)
JP2000256194A (ja) 核内レセプタ作動薬およびその効果増強剤
EA016887B1 (ru) ЗАМЕЩЁННЫЕ ФЕНОКСИАМИНОТИАЗОЛОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ РОДСТВЕННОГО ЭСТРОГЕНОВОМУ РЕЦЕПТОРУ РЕЦЕПТОРА-α
JP2023506787A5 (cg-RX-API-DMAC10.html)
TW201607943A (zh) 作為ep4配體之新穎苯并咪唑衍生物
JP2014501732A (ja) 骨癌の疼痛におけるシグマリガンドの使用
JP2009516747A5 (cg-RX-API-DMAC10.html)
JP2015517523A5 (cg-RX-API-DMAC10.html)
US10172814B2 (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
JP2024538730A5 (cg-RX-API-DMAC10.html)
JP2002522423A (ja) α1A作動薬としてのイミダゾール及び関連化合物
Zbieg et al. Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer
JP2025510512A5 (cg-RX-API-DMAC10.html)
Guo et al. Estrogen Receptor α (ERα)-targeting compounds and derivatives: Recent advances in structural modification and bioactivity
US10793525B2 (en) 13-cis-RAMBA retinamides that degrade MNKs for treating cancer